Belfast Health and Social Care Trust
caring supporting improving together

FOI/38603

29 October 2026

ANALYSIS ON TREATMENT WITH IMMUNOLOGY MEDICINES

I am conducting analysis on treatment with dermatology medicines and kindly request your help.

I would be grateful if you could tell me how many patients were treated in the 3 months between July and September 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	**Total** number of patients treated **regardless of diagnosis**
Adalimumab	217
Abrocitinib	10
Apremilast	<5
Baricitinib	<5
Bimekizumab	12
Brodalumab	0
Certolizumab Pegol	6
Deucravacitinib	<5
Dupilumab	256
Etanercept	<5
Guselkumab	65
Icotrokinra	0
Infliximab	8
Ixekizumab	40
Lebrikizumab	0
Nemolizumab	11
Risankizumab	83
Secukinumab	41
Tildrakizumab	0
Tralokinumab	0
Ustekinumab	<5

29 October 2026

Q2. How many patients were treated by the Dermatology Department with the following drugs between 1st July 2026 and 30th September 2026?

Drug Name	Number of patients treated by the **Dermatology Department**
Adalimumab	217
Apremilast	<5
Baricitinib	<5
Bimekizumab	12
Brodalumab	0
Certolizumab Pegol	6
Dupilumab	256
Etanercept	<5
Guselkumab	65
Infliximab	8
Ixekizumab	40
Omalizumab	8
Risankizumab	83
Secukinumab	41
Upadacitinib	50
Ustekinumab	<5

Q3. How many patients with Plaque Psoriasis across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with **Plaque Psoriasis**
Adalimumab	168
Apremilast	<5
Bimekizumab	11
Brodalumab	0
Certolizumab Pegol	6
Etanercept	<5
Guselkumab	64
Infliximab	0
Ixekizumab	39
Risankizumab	83
Secukinumab	25
Ustekinumab	<5

29 October 2026

Q4. How many patients with Atopic Dermatitis across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number Patients **Atopic Dermatitis**
Baricitinib	0
Dupilumab	244
Nemolizumab	<5
Upadacitinib	<5

Q5. How many patients with Hidradenitis Suppurativa across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number Patients **Hidradenitis Suppurativa**
Adalimumab	40
Bimekizumab	<5
Secukinumab	15

Q6. How many patients with Chronic Spontaneous Urticaria across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number Patients **Chronic Spontaneous Urticaria**
Dupilumab	<5
Omalizumab	9
Remibrutinib	0

Where numbers are low, we have indicated <5 rather than provide the exact figure. Releasing such small numbers has the potential to make people identifiable and disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018. This information is therefore exempt from release under Section 40(2) of the Freedom of Information Act 2000 – Information Relating to a Third Party.